Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2017; 63(2): 95-104

EPIGENETICS OF ARTERIAL HYPERTENSION

M.V.Khaitovych1, A.P. Burlaka2, V.S.Potaskalova1

  1. Bogomolets National Medical University, Kyiv;
  2. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine, Kyiv
DOI: https://doi.org/10.15407/fz63.02.095


Abstract

The literature review summarizes modern data which deals with the role of epigenetic influences (DNA methylation, posttranslational modification of histones, RNA interference) in case of mechanism of primary arterial hypertension (AH) development. It has been pointed out the contribution of oxidative stress (OS) in disturbance of transcriptional and posttranscriptional regulation in case of AH; the role of hyperhomocysteinemia in formation of vascular stiffness. It has been described the mechanisms of regulation of cytoprotective role of autophagy. Underlying the epigenetic influences, the following approaches are perspective: 1) prophylactic and treatment AH with administration of resveratrol (activates SIRT1 and decreases OS, increases activity of endothelial NO-synthase); folates (prevent hypomethylation of DNA); probiotics (action on microRNA); melatonin (decreases demethylation of endothelial NO-synthase promotor); 2) prevention of disease progression - use of inhibitors of DNA methylation and autophagy modulators (reduce fibrosis and hypertrophy of myocardium).

Keywords: epigenetics; arterial hypertension.

Full text: (PDF, in Ukrainian)

References

  1. Scherrer U, Rimoldi SF, Sartori C, Messerli FH, Rexhaj E. Fetal programming and epigenetic mechanisms in arterial hypertension. Curr Opin Cardiol. 2015; 30(4): 393 – 7. CrossRef PubMed
    2.  
  2. Vayserman AM, Voytenko VP, Mehova LV. Epigeneticheskaya epidemiologiya vozrast-zavisimyih zabolevaniy. Ontogenez. 2011, 42 (1): 1–21. [Russian].
    3.  
  3. Smith C.J., Ryckman K.K. Epigenetic and developmental influences on the risk of obes. ity, diabetes, and metabolic syndrome. Diabetes, Metabolic Syndr and Obes: Targ and Ther. 2015; 8; 295–302.
    4.  
  4. Leow MK. Environmental origins of hypertension: phylogeny, ontogeny and epigenetics. Hypertens Res. 2015; 38(5): 299 – 307. CrossRef PubMed
    5.  
  5. Friso S, Carvajal CA, Fardella CE, Olivieri O. Epigenetics and arterial hypertension: the challenge of emerging evidence. Transl Res. 2015; 165(1): 154 –65. CrossRef PubMed
    6.  
  6. Nistala R, Hayden MR, Demarco VG, Henriksen EJ, Lackland DT, Sowers JR. Prenatal Programming and Epigenetics in the Genesis of the Cardiorenal Syndrome. Cardiorenal Med. 2011; 1(4): 243 – 54. CrossRef PubMed PubMedCentral
    7.  
  7. Belyaeva LE. Epigeneticheskie mehanizmyi i fenotip. Fundamentalnyie i prikladnyie problemyi stressa: materialyi III Mezhdunar. nauch.-prakt. konf., Vitebsk, 16-17 aprelya 2013g. – Vitebsk: VGU imeni P.M. Masherova, 2013: 124-6. [Russian].
    8.  
  8. Olzscha H, Sheikh S, La Thangue NB. Deacetylation of chromatin and gene expression regulation: a new target for epigenetic therapy. Crit Rev Oncog. 2015; 20(1-2): 1–17. CrossRef PubMed
    9.  
  9. Vanyushin BF. Epigenetika segodnya i zavtra. Vavil Zhur Genet i Selekt. 2013; 17 (4/2): 805–832. [Russian].
    10.  
  10. Yang JY, Wang Q, Wang W, Zeng LF. Histone deacetylases and cardiovascular cell lineage commitment. World J Stem Cells. 2015; 7(5): 852–8. CrossRef PubMed PubMedCentral
    11.  
  11. Khavinson VKh, Lin'kova NS, Morozova EA, Gutop EO, Elashkina EV. Molecular mechanisms of cardiovascular disease. Usp Fiziol Nauk. 2014; 45(3): 57–65. PubMed
    12.  
  12. Magenta A., Greco S., Gaetano C., Martelli F. Oxidative Stress and MicroRNAs in Vascular Diseases. Int J Mol Sci. 2013; 14(9): 17319–46. CrossRef PubMed PubMedCentral
    13.  
  13. Raftopoulos L, Katsi V, Makris T, Tousoulis D, Stefanadis C, Kallikazaros I. Epigenetics, the missing link in hypertension. Life Sci. 2015; 129: 22–6. CrossRef PubMed
    14.  
  14. Schleithoff C., Voelter-Mahlknecht S., Dahmke I. Mahlknecht U. On the epigenetics of vascular regulation and disease. Clin Epigen. 2012; 4: 7. CrossRef PubMed PubMedCentral
    15.  
  15. Johnson AK, Zhang Z, Clayton SC, Beltz TG, Hurley SW, Thunhorst RL, Xue B. The Roles of Sensitization and Neuroplasticity in the Long-Term Regulation of Blood Pressure and Hypertension. Am J Physiol Regul Integr Comp Physiol. 2015; 309(11): 1309–25. CrossRef PubMed PubMedCentral
    16.  
  16. Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 2011; 25: 1345-58. CrossRef PubMed PubMedCentral
    17.  
  17. Kim GH1, Ryan JJ, Archer SL. The role of redox signaling in epigenetics and cardiovascular disease. Antioxid Redox Signal. 2013; 18(15): 1920–36. CrossRef PubMed PubMedCentral
    18.  
  18. Xu Y. Transcriptional regulation of endothelial dysfunction in atherosclerosis: an epigenetic perspective. J Biomed Res. 2014; 28(1): 47–52. PubMed
    19.  
  19. Orlov SN., Koltsova SV, Kapilevich LV, Dulin NO, Gusakova SV. Kotransporteryi kationov i hlora: regulyatsiya, fiziologicheskoe znachenie i rol v patogeneze arterialnoy gipertenzii. Usp biolog him. 2014, 54: 267–98. [Russian].
    20.  
  20. Martin M.M., Buckenberger J.A., Jiang J. et al. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding. J Biol Chem. 2007; 282(33): 24262–9. CrossRef PubMed PubMedCentral
    21.  
  21. Sethupathy P., Borel C., Gagnebin M. et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional singlenucleotide polymorphisms related to phenotypes. Am J Hum Genet. 2007; 81: 405–13. CrossRef PubMed PubMedCentral
    22.  
  22. Duthie SJ. Epigenetic modifications and human pathologies: cancer and CVD. Proc Nutr Soc. 2011; 70(1): 47–56. CrossRef PubMed
    23.  
  23. Narayanan N, Pushpakumar SB, Givvimani S, Kundu S, Metreveli N, James D, et al. Epigenetic regulation of aortic remodeling in hyperhomocysteinemia. FASEB J. 2014; 28(8): 3411–22. CrossRef PubMed PubMedCentral
    24.  
  24. Majumder S, Advani A. The epigenetic regulation of podocyte function in diabetes. J Diabetes Complications. 2015; 29(8): 1337–44. CrossRef PubMed
    25.  
  25. Chang PY, Chen YJ, Chang FH, Lu J, Huang WH, Yang TC, et al. Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. Cardiovasc Res. 2013; 99(1): 137–45. CrossRef PubMed
    26.  
  26. Ohtani K, Vlachojannis GJ, Koyanagi M, Boeckel JN, Urbich C, Farcas R, et al. Epigenetic regulation of endothelial lineage committed genes in pro-angiogenic hematopoietic and endothelial progenitor cells. Circ Res. 2011; 109(11): 1219–29. CrossRef PubMed
    27.  
  27. Zhang W.Epigenetics of epithelial Na(+) channeldependent sodium uptake and blood pressure regulation. World J Nephrol. 2015; 4(3): 363–6. CrossRef PubMed PubMedCentral
    28.  
  28. Nallamshetty S, Chan SY, Loscalzo J. Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med. 2013; 64: 20–30. CrossRef PubMed PubMedCentral
    29.  
  29. Bennett MR. Cell death in cardiovascular disease. Arterioscler Thromb Vasc Biol. 2011; 31: 2779–80. CrossRef PubMed
    30.  
  30. Marcu R, Kotha S, Zhi Z, Qin W, Neeley CK, Wang RK et al. The mitochondrial permeability transition pore regulates endothelial bioenergetics and angiogenesis. Circ Res. 2015; 116(8): 1336–45. CrossRef PubMed PubMedCentral
    31.  
  31. Ortega Ávila JG, Echeverri I, de Plata CA, Castillo A. Impact of oxidative stress during pregnancy on fetal epigenetic patterns and early origin of vascular diseases. Nutr Rev. 2015; 73(1): 12–21. CrossRef PubMed
    32.  
  32. Macconi D, Remuzzi G, Benigni A .Key fibrogenic mediators: old players. Renin-angiotensin system. Kidney Int Suppl (2011). 2014; 4(1): 58–64. CrossRef PubMed PubMedCentral
    33.  
  33. Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J. 2012;441: 523–40. CrossRef PubMed PubMedCentral
    34.  
  34. Wang S1, Xia P, Rehm M, Fan Z. Autophagy and cell reprogramming. Cell Mol Life Sci. 2015; 72(9): 1699-713. CrossRef PubMed
    35.  
  35. Lapierre LR, Kumsta C, Sandri M, Ballabio A, Hansen M.Transcriptional and epigenetic regulation of autophagy in aging. Autophagy. 2015; 11(6): 867–80. CrossRef PubMed PubMedCentral
    36.  
  36. Li Z, Song Y, Liu L, Hou N, An X, Zhan D, et al. miR- 199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. Cell Death Differ. 2015. [doi: 10.1038/cdd.2015.95]. CrossRef  
  37. Wang J, Gong L, Tan Y, Hui R, Wang Y. Hypertensive epigenetics: from DNA methylation to microRNAs. J Hum Hypert. 2015. [doi:10.1038/jhh.2014.132]. CrossRef  
  38. Tyagi SC, Joshua IG. Exercise and nutrition in myocardial matrix metabolism, remodeling, regeneration, epigenetics, microcirculation, and muscle. Can J Physiol Pharmacol. 2014; 92(7): 521–3. CrossRef PubMed
    39.  
  39. Santilli F, Guagnano MT, Vazzana N, La Barba S, Davi G. Oxidative stress drivers and modulators in obesity and cardiovascular disease: from biomarkers to therapeutic approach. Curr Med Chem. 2015; 22(5): 582–95. CrossRef PubMed
    40.  
  40. Das M, Das DK: Resveratrol and cardiovascular health. Mol Aspects Med. 2010; 31(6): 503–12. CrossRef PubMed
    41.  
  41. Suzuki H, et al.: DNA methylation and cancer pathways in gastrointestinal tumors. Pharmacogenomics. 2008; 9(12): 1917–28. CrossRef PubMed
    42.  
  42. Rexhaj E, Pireva A, Paoloni-Giacobino A, Allemann Y, Cerny D, Dessen P, et al. Prevention of vascular dysfunction and arterial hypertension in mice generated by assisted reproductive technologies by addition of melatonin to culture media. Am J Physiol Heart Circ Physiol. 2015; 309(7): 1151-6. CrossRef PubMed
    43.  
  43. Wu Z, Siuda D, Xia N, Reifenberg G, Daiber A, Münzel T, et al. Maternal treatment of spontaneously hypertensive rats with pentaerythritol tetranitrate reduces blood pressure in female offspring. Hypertension. 2015; 65(1): 232–7. CrossRef PubMed
    44.  
  44. Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens. 2015; 24(5): 403–9. CrossRef PubMed PubMedCentral
    45.  
  45. Stein S, et al.: SIRT1 reduces endothelial activation without affecting vascular function in ApoE−/− mice. Aging (Albany NY). 2010; 2(6): 353–60. CrossRef PubMed PubMedCentral
    46.  
  46. Nikolic D, Rizzo M, Mikhailidis DP, Wong NC, Banach M. An evaluation of RVX-208 for the treatment of atherosclerosis. Expert Opin Investig Drugs. 2015; 24(10): 1389–98. CrossRef PubMed
    47.  
  47. Watson CJ, Horgan S, Neary R, Glezeva N, Tea I, Corrigan N, et al. Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis. J Cardiov Pharmacol Ther. 2016; 21(1): 127–37. CrossRef PubMed
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.